A new vaccine has the potential to treat and prevent toxic shock caused by invasive streptococcal disease, which kills more than 160,000 people every year. When ISD occurs, some strains can make more toxins than others and cause streptococcal toxic shock syndrome (STSS). Now that antibodies have been generated, the next step would be to make monoclonal antibodies that could be suitable for a human trial study of the vaccine’s efficacy.
